“Far-reaching impacts” of Federal Circuit ruling on ANDA personal jurisdiction
The Federal Circuit ruling in Acorda v Mylan and AstraZeneca v Mylan gives branded pharmaceutical companies more flexibility in their choice of where to file suit against generics
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
